Table 1.
Clinicopathological characteristics of patients and treatment modalities
| Variablesa | n (%) | 5YRS | PFS, P d | 5YRS | OS, P d | |
|---|---|---|---|---|---|---|
| (Total = 114) | PFS (SD) | OS (SD) | ||||
| Age (yr) | ≤50 | 23 (20.2) | 0.684 (0.108) | 0.072 | 0.909 (0.043) | 0.126 |
| >50 | 91 (79.8) | 0.334 (0.090) | 0.698 (0.086) | |||
| Age (yr) | ≤60 | 55 (48.2) | 0.498 (0.081) | 0.585 | 0.854 (0.065) | 0.014 |
| >60 | 59 (51.8) | 0.217 (0.167) | 0.569 (0.172) | |||
| Sex | M | 65 (57.0) | 0.452 (0.086) | 0.708 | 0.849 (0.054) | 0.156 |
| F | 49 (43.0) | 0.460 (0.112) | 0.452 (0.168) | |||
| Initial Symptoms | Headache &vomiting | 30 (26.3) | 0.609 (0.114) | 0.400 | 0.870 (0.071) | 0.266 |
| Seizure | 6 (5.3) | 0.000 (0.000) | 100.0 | |||
| Neurologic deficit | 78 (68.4) | 0.387 (0.085) | 0.697 (0.085) | |||
| ECOG PS | 0, 1 | 73 (65.2) | 0.425 (0.086) | 0.818 | 0.789 (0.075) | 0.247 |
| 2–4 | 39 (34.8) | 0.511 (0.135) | 0.752 (0.079) | |||
| KPS | ≥70 | 97 (87.4) | 0.468 (0.082) | 0.001 | 0.760 (0.065) | 0.854 |
| <70 | 14 (12.6) | 0.259 (0.144) | 0.821 (0.117) | |||
| B Symptoms | Absent | 109 (95.6) | 0.452 (0.073) | 0.284 | 0.768 (0.061) | 0.558 |
| Present | 5 (4.4) | 0.333 (0.272) | 0.800 (0.179) | |||
| Serum LDH | Normal | 68 (63.6) | 0.223 (0.087) | 0.005 | 0.767 (0.102) | 0.201 |
| Elevated | 39 (36.4) | 0.675 (0.102) | 0.760 (0.100) | |||
| Cell of origin | GCB | 24 (21.2) | 0.689 (0.120) | 0.073 | 0.795 (0.092) | 0.957 |
| Non-GCB | 89 (78.8) | 0.383 (0.082) | 0.756 (0.074) | |||
| Involvement of deep structure | Absent | 30 (26.3) | 0.441 (0.161) | 0.219 | 0.758 (0.129) | 0.640 |
| Present | 84 (73.7) | 0.433 (0.078) | 0.762 (0.070) | |||
| Extent of disease | Unifocal | 42 (36.8) | 0.553 (0.119) | 0.037 | 0.753 (0.137) | 0.603 |
| Multifocal | 72 (63.2) | 0.368 (0.088) | 0.782 (0.062) | |||
| Ocular involvement | Absent | 101 (89.4) | 0.485 (0.072) | 0.985 | 0.872 (0.046) | 0.466 |
| Present | 12 (10.6) | 0.233 (0.190) | 0.525 (0.204) | |||
| CSF protein | Normal | 39 (42.4) | 0.291 (0.142) | 0.988 | 0.675 (0.141) | 0.340 |
| Elevated | 53 (57.6) | 0.467 (0.090) | 0.849 (0.058) | |||
| CSF cytology | Negative | 82 (85.4) | 0.356 (0.083) | 0.281 | 0.774 (0.066) | 0.693 |
| Positive | 14 (14.6) | 0.608 (0.158) | 0.711 (0.180) | |||
| IELSG | 0–2 | 43 (47.3) | 0.229 (0.100) | 0.093 | 0.853 (0.101) | 0.054 |
| 3–5 | 48 (52.7) | 0.638 (0.088) | 0.736 (0.074) | |||
| Nottingham– Barcelona | 0–1 | 53 (47.3) | 0.604 (0.097) | 0.001 | 0.807 (0.080) | 0.188 |
| 2–3 | 59 (52.7) | 0.264 (0.098) | 0.723 (0.084) | |||
| MSKCC class | 1 | 21 (18.4) | 0.760 (0.106) | 0.008 | 0.847 (0.108) | 0.157 |
| 2–3 | 91 (79.8) | 0.340 (0.086) | 0.688 (0.095) | |||
| Radiotherapy | Not done | 36 (31.6) | 0.586 (0.142) | 0.854 | 0.758 (0.086) | 0.057 |
| Done | 78 (68.4) | 0.416 (0.080) | 0.787 (0.068) | |||
| Chemotherapy | MVPb | 79 (81.4) | 0.431 (0.084) | 0.519 | 0.772 (0.072) | 0.940 |
| HD-MTX | 14 (14.4) | 0.442 (0.176) | 0.791 (0.138) | |||
| Othersc | 4 (4.1) | 0.750 (0.217) | 100.0 | |||
| Rituximab | Not done | 103 (90.4) | 0.453 (0.074) | 0.756 | 0.748 (0.067) | 0.503 |
| Done | 11 (9.6) | 0.333 (0.248) | 0.909 (0.087) | |||
| IT-MTX | Not done | 89 (78.1) | 0.412 (0.092) | 0.649 | 0.743 (0.076) | 0.415 |
| Done | 25 (21.9) | 0.457 (0.114) | 0.832 (0.089) |
Abbreviations: ECOG PS The Eastern Cooperative Oncology Group performance score, KPS Karnofsky performance status score, LDH lactate dehydrogenase, GCB germinal center B cell-like, CSF cerebrospinal fluid, IELSG the International Extranodal Lymphoma Study group, MSKCC Memorial Sloan Kettering Cancer Center, MVP combined chemotherapy regimen of high-dose methotrexate, vincristine and procarbazine, HD-MTX high-dose methotrexate, IT-MTX intrathecal methotrexate, PFS progression-free survival, OS overall survival
aSome cases have missing values that lacked the information about the variables
bIncludes 8 patients who received rituximab-MVP
cOthers include COPADM and CHOP
dPFS and OS were analyzed using the Kaplan-Meier method with the log-rank test